Fundraising Fox
/People
Sign in

Michel Detheux

Founder

Chairman at Egle Tx · Chief Executive Officer & Board Director at Muna Therapeutics · Founder at iTeos Therapeutics

Denmark

FoundediTeos Therapeutics

Find your path to Michel

272 people in our graph share verified history with Michel — schools, employers, funds. One of them is your warm intro.

Detlev BiniszkiewiczunlockedMichel: together at iTeos Therapeutics (2019–2023)
×3Michel: together at iTeos Therapeutics
×2Michel: together at Ona Therapeutics
×4Michel: together at Muna Therapeutics

About

Michel Detheux, Ph.D., is CEO of Muna Therapeutics, which develops treatments for neurodegenerative diseases. He co-founded iTeos Therapeutics and served as its President and CEO, overseeing its progression from preclinical stages to late-stage clinical development, including a NASDAQ IPO and a co-development and co-commercialization agreement with GlaxoSmithKline for the anti-TIGIT antibody belrestotug; earlier in his career he held roles at Ludwig Cancer Research and Ogeda (formerly Euroscreen). He currently serves as chairman and board member for Egle Therapeutics, Vor Bio, and MRM Health, holds a B.S. in Bioengineering and a Ph.D. in Biochemistry from the Catholic University of Louvain, and is the author of 51 peer-reviewed publications and inventor on 27 patent applications.

Chairman at Egle Tx

Intro paths

→

In turn, Michel can intro founders to Egle Tx's investors below.

Egle Tx's investors · 3

EQT Life SciencesLuxembourg · $11M – $66M checksFund+Leuven · $5.5M – $16.5M checksJDRF T1D FundBoston

Chief Executive Officer & Board Director at Muna Therapeutics

Intro paths

→

In turn, Michel can intro founders to Muna Therapeutics's investors below.

Muna Therapeutics's investors · 4

Droia VenturesLuxembourg · $540K checksSanofi VenturesCambridge · $5M checksSofinnova PartnersParis · $540K – $27M checksV-Bio VenturesGhent · $270K – $2.2M checks

Co-founders at Muna Therapeutics

RBRita Balice-Gordon
Rita Balice-GordonFounder
JVJoachim Vilstrup
Joachim VilstrupHead of Protein Chemistry and Structural Biology; scientific co-founder

Founder at iTeos Therapeutics

Intro paths

→

In turn, Michel can intro founders to iTeos Therapeutics's investors below.

iTeos Therapeutics's investors · 10

6 Dimensions CapitalGrand Cayman · since 2020Curative VenturesDallas · since 2020Fund+Leuven · $5.5M – $16.5M checks · since 2020HBM PartnersZug · $5M – $50M checks · since 2020InvusNew York · since 2020Janus Henderson InvestorsNew York · since 2020MPM BioImpactBoston · $1M – $15M checks · since 2020RA CapitalBoston · since 2020RTW Investments L.P.New York · since 2020VIVES PartnersWavre · $108K – $7.6M checks · since 2020

Experience

  1. Muna TherapeuticsCEO*current2026 — presentCopenhagen Metropolitan Area
  2. MRM HealthChair of the Board of Directors*current2026 — presentGhent Metropolitan Area
  3. BioForge Consulting SRLManaging Directorcurrent2026 — presentBelgium
  4. Vor BioMember Board of Directorscurrent2025 — presentBoston, Massachusetts, United States
  5. Egle TherapeuticsChair Of The Board Of Directorscurrent2024 — presentParis, France
  6. iTeos Therapeutics SACo-founder, President & CEO2019 — 2026Watertown, Massachusetts, United States
  7. iTeos Therapeutics SACo-founder & CEO*2012 — 2019Gosselies Belgium
  8. ONA TherapeuticsChair Of The Board Of Directors2021 — 2024Barcelona, Catalonia, Spain
  9. InnoskelChair Of The Board Of Directors2022 — 2023Biot, Provence-Alpes-Côte d'Azur, France
  10. MG6A Bioconsulting SPRLFounder and Managing Director2012 — 2019Belgium
  11. BioWinDirector of the Board*2016 — 2018Belgium
  12. ImmuneHealthIndependent Board Member*2014 — 2016Gosselies Belgium
  13. Ludwig Cancer ResearchDirector, Spin off project2010 — 2012
  14. EuroscreenDirector Euroscreen FAST Business Unit2006 — 2010
  15. EuroscreenManager, New Business Opportunities2005 — 2006
  16. EuroscreenHead of Target Discovery1995 — 2004
  17. University of GlasgowPost doctoral fellow1993 — 1994

Skills & more

Start-ups19Drug Discovery43Cancer Immunotherapy6Biotechnology36Business Development14R&D14Fundraising

Languages English · French

From Michel's professional profile.

Frequently asked questions

Who is Michel Detheux?
Michel Detheux, Ph.D., is CEO of Muna Therapeutics, which develops treatments for neurodegenerative diseases. He co-founded iTeos Therapeutics and served as its President and CEO, overseeing its progression from preclinical stages to late-stage clinical development, including a NASDAQ IPO and a co-development and co-commercialization agreement with GlaxoSmithKline for the anti-TIGIT antibody belrestotug; earlier in his career he held roles at Ludwig Cancer Research and Ogeda (formerly Euroscreen). He currently serves as chairman and board member for Egle Therapeutics, Vor Bio, and MRM Health, holds a B.S. in Bioengineering and a Ph.D. in Biochemistry from the Catholic University of Louvain, and is the author of 51 peer-reviewed publications and inventor on 27 patent applications.
Where does Michel Detheux work?
Michel Detheux is Founder of iTeos Therapeutics and Chairman at Egle Tx and Chief Executive Officer & Board Director at Muna Therapeutics.
What companies did Michel Detheux found?
Michel Detheux founded iTeos Therapeutics.
Where did Michel Detheux go to school?
Michel Detheux studied at Solvay Brussels School of Economics and Management (CEPAC, Business/management); University of Glasgow (Post doc, Parasitology); Université catholique de Louvain (PhD, Biochemistry).

Founder mafias

Same school

Shared employers